Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease
© 2024. The Author(s)..
PURPOSE: Besides the well-established efficacy in preventing severe COVID-19, the impact of early treatments, namely antivirals and monoclonal antibodies (mAbs), on the time length to negativization of SARS-CoV-2 nasal swabs is still unclear. The aim of this study was to compare the efficacy of different early treatments in reducing the SARS-CoV-2 viral shedding, identifying a single drug that might potentially lead to a more rapid negativization of SARS-CoV-2 nasal swab.
METHODS: This was a single-centre, retrospective, observational study conducted at Ospedale Luigi Sacco in Milan. Data of high-risk COVID-19 patients who received early treatments between 23 December 2021 and March 2023 were extracted. The comparison across treatments was conducted using the Kruskall-Wallis test for continuous variables. Dunn's test with Bonferroni adjustment was performed for post-hoc comparisons of days to negativization. Secondly, a negative binomial regression adjusted for age, sex, number of comorbidities, immunosuppression, and SARS-CoV-2 vaccination status was implemented.
RESULTS: Data from 428 patients receiving early treatments were collected. The majority were treated with Nirmatrelvir/Ritonavir and were affected by SARS-CoV-2 Omicron infection with BA.2 sublineage. The median length time to SARS-CoV-2 nasal swab negativization was 9 days [IQR 7-13 days]. We found that Nirmatrelvir/Ritonavir determined a significant decrease of the length time to SARS-CoV-2 nasal swab negativization compared to mAbs (p = 0.003), but not compared to Remdesivir (p = 0.147) and Molnupiravir (p = 0.156).
CONCLUSION: Our findings highlight the importance of promptly treating high-risk COVID-19 patients with Nirmatrelvir/Ritonavir, as it also contributes to achieving a faster time to negative SARS-CoV-2 nasal swabs.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
---|---|
Enthalten in: |
Virology journal - 21(2024), 1 vom: 20. März, Seite 68 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Colaneri, Marta [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 22.03.2024 Date Revised 23.03.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12985-024-02333-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM36999115X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM36999115X | ||
003 | DE-627 | ||
005 | 20240323235551.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240322s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12985-024-02333-x |2 doi | |
028 | 5 | 2 | |a pubmed24n1342.xml |
035 | |a (DE-627)NLM36999115X | ||
035 | |a (NLM)38509536 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Colaneri, Marta |e verfasserin |4 aut | |
245 | 1 | 0 | |a Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.03.2024 | ||
500 | |a Date Revised 23.03.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s). | ||
520 | |a PURPOSE: Besides the well-established efficacy in preventing severe COVID-19, the impact of early treatments, namely antivirals and monoclonal antibodies (mAbs), on the time length to negativization of SARS-CoV-2 nasal swabs is still unclear. The aim of this study was to compare the efficacy of different early treatments in reducing the SARS-CoV-2 viral shedding, identifying a single drug that might potentially lead to a more rapid negativization of SARS-CoV-2 nasal swab | ||
520 | |a METHODS: This was a single-centre, retrospective, observational study conducted at Ospedale Luigi Sacco in Milan. Data of high-risk COVID-19 patients who received early treatments between 23 December 2021 and March 2023 were extracted. The comparison across treatments was conducted using the Kruskall-Wallis test for continuous variables. Dunn's test with Bonferroni adjustment was performed for post-hoc comparisons of days to negativization. Secondly, a negative binomial regression adjusted for age, sex, number of comorbidities, immunosuppression, and SARS-CoV-2 vaccination status was implemented | ||
520 | |a RESULTS: Data from 428 patients receiving early treatments were collected. The majority were treated with Nirmatrelvir/Ritonavir and were affected by SARS-CoV-2 Omicron infection with BA.2 sublineage. The median length time to SARS-CoV-2 nasal swab negativization was 9 days [IQR 7-13 days]. We found that Nirmatrelvir/Ritonavir determined a significant decrease of the length time to SARS-CoV-2 nasal swab negativization compared to mAbs (p = 0.003), but not compared to Remdesivir (p = 0.147) and Molnupiravir (p = 0.156) | ||
520 | |a CONCLUSION: Our findings highlight the importance of promptly treating high-risk COVID-19 patients with Nirmatrelvir/Ritonavir, as it also contributes to achieving a faster time to negative SARS-CoV-2 nasal swabs | ||
650 | 4 | |a Observational Study | |
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Immunosuppression | |
650 | 4 | |a Monoclonal antibodies | |
650 | 4 | |a Nirmatrelvir/Ritonavir | |
650 | 4 | |a Time to negativization | |
650 | 7 | |a nirmatrelvir |2 NLM | |
650 | 7 | |a 7R9A5P7H32 |2 NLM | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Ritonavir |2 NLM | |
650 | 7 | |a O3J8G9O825 |2 NLM | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Lactams |2 NLM | |
650 | 7 | |a Leucine |2 NLM | |
650 | 7 | |a GMW67QNF9C |2 NLM | |
650 | 7 | |a Nitriles |2 NLM | |
650 | 7 | |a Proline |2 NLM | |
650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
700 | 1 | |a Scaglione, Giovanni |e verfasserin |4 aut | |
700 | 1 | |a Fassio, Federico |e verfasserin |4 aut | |
700 | 1 | |a Galli, Lucia |e verfasserin |4 aut | |
700 | 1 | |a Lai, Alessia |e verfasserin |4 aut | |
700 | 1 | |a Bergna, Annalisa |e verfasserin |4 aut | |
700 | 1 | |a Gabrieli, Arianna |e verfasserin |4 aut | |
700 | 1 | |a Tarkowski, Maciej |e verfasserin |4 aut | |
700 | 1 | |a Ventura, Carla Della |e verfasserin |4 aut | |
700 | 1 | |a Colombo, Valeria |e verfasserin |4 aut | |
700 | 1 | |a Cordier, Laura |e verfasserin |4 aut | |
700 | 1 | |a Bernasconi, Davide |e verfasserin |4 aut | |
700 | 1 | |a Corbellino, Mario |e verfasserin |4 aut | |
700 | 1 | |a Dedivitiis, Gianfranco |e verfasserin |4 aut | |
700 | 1 | |a Borghetti, Silvia |e verfasserin |4 aut | |
700 | 1 | |a Visigalli, Debora |e verfasserin |4 aut | |
700 | 1 | |a Sollima, Salvatore |e verfasserin |4 aut | |
700 | 1 | |a Casalini, Giacomo |e verfasserin |4 aut | |
700 | 1 | |a Rizzardini, Giuliano |e verfasserin |4 aut | |
700 | 1 | |a Gori, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Antinori, Spinello |e verfasserin |4 aut | |
700 | 1 | |a Riva, Agostino |e verfasserin |4 aut | |
700 | 1 | |a Schiavini, Monica |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Virology journal |d 2004 |g 21(2024), 1 vom: 20. März, Seite 68 |w (DE-627)NLM151772509 |x 1743-422X |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2024 |g number:1 |g day:20 |g month:03 |g pages:68 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12985-024-02333-x |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 21 |j 2024 |e 1 |b 20 |c 03 |h 68 |